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BACKGROUND No studies assessed impact of atrial flutter (AFL)
ablation on outcomes in patients with AFL and concurrent heart fail-
ure (HF).
OBJECTIVES To assess the effect of AFL ablation on mortality and
HF readmissions in patients with AFL and HF.
METHODS This retrospective cohort study identified 15,952 pa-
tients with AFL and HF from the 2016–17 Nationwide Readmissions
Database. The primary outcome was a composite of all-cause mor-
tality and/or HF readmission at 1 year. Secondary outcomes
included HF readmission, all-cause mortality, and atrial fibrillation
(AF) readmission at 1 year. Propensity score match (1:2) algorithm
was used to adjust for confounders. Cox proportional hazard regres-
sion was used to generate hazard ratios.
RESULTS Of the 15,952 patients, 9889 had heart failure with
reduced ejection fraction (HFrEF) and 6063 had heart failure with
preserved ejection fraction (HFpEF). In the matched HFrEF cohort
(n5 5421), the primary outcome was significantly lower in patients
undergoing ablation (HR 0.72, 95% CI 0.61–0.85, P, .001). HF re-
admission (HR 0.73, 95% CI 0.61–0.89, P5 .001), all-cause mortal-
ity (HR 0.62, 95% CI 0.46–0.85, P5 .003), and AF readmission (HR
0.63, 95% CI 0.48–0.82, P5 .001) were also significantly reduced.
In the matched HFpEF cohort (n5 2439), the primary outcome was
lower in the group receiving ablation but was not statistically sig-
nificant (HR 0.80, 95% CI 0.63–1.01, P 5 .065).
CONCLUSION In patients with AFL and HFrEF, AFL ablation was
associated with lower mortality and HF readmissions at 1 year. Pa-
tients with AFL and HFpEF did not show a similar significant reduc-
tion in the primary outcome.
KEYWORDS Atrial flutter; Catheter ablation; Heart failure; Nation-
wide Readmissions Database
(Heart Rhythm O2 2021;2:53–63) © 2020 Published by Elsevier Inc.
on behalf of Heart Rhythm Society. This is an open access article un-
der the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
Atrial flutter (AFL) occurs frequently in the setting of heart
failure (HF) and is associated with an increased risk of stroke,
HF, and, subsequently, morbidity and mortality.1,2 The struc-
tural, electrophysiologic, and neuroendocrine changes gener-
ated by HF facilitate the development and progression of
AFL and each condition promotes the other, leading to a
vicious cycle of self-propagation.3 Patients admitted with de-
compensated HF in typical AFL and rapid ventricular rates
are often referred for ablation, yet outcomes data in this group
are lacking. Urgent intervention with catheter ablation and/or
pharmacotherapy has been hypothesized to halt disease pro-
gression and improve mortality. A prior, small prospective
randomized trial comparing pharmacotherapy with ablation
in patients with AFL demonstrated that ablation was able to
restore sinus rhythm, lower readmission rates, decrease
development of atrial fibrillation (AF), and overall improve
quality of life.4 Subsequent studies have supported catheter
ablation as being safe and efficacious, but there is a lack of
data regarding long-term outcomes such as mortality or read-
mission rates.5 Motivated by this gap in understanding the
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quests and correspondence:Dr Judith A. Mackall, Division of Cardiology,
Department ofMedicine, HarringtonHeart andVascular Institute, University
Hospitals Cleveland Medical Center, Case Western Reserve University,
11100 Euclid Avenue, Cleveland, OH 44106-5038. E-mail address: judith.
mackall@uhhospitals.org.
2666-5018/© 2020 Published by Elsevier Inc. on behalf of Heart Rhythm Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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impact of AFL ablation, this retrospective study seeks to un-
derstand and quantify the effects of catheter ablation for pa-
tients with AFL and concurrent HF.
Methods
Data source
Data were extracted from the 2016–17 Nationwide Readmis-
sion Database (NRD). NRD is a subset of the Healthcare Cost
and Utilization Project (HCUP), sponsored by the Agency for
Healthcare Research and Quality. The NRD from years
2016–17 contains data from approximately 17 million dis-
charges, across 28 geographically dispersed states, and ac-
counts for 60% of the total US resident population and
58.2% of all US hospitalizations.6 The NRD has been studied
and validated in multiple previous studies.7,8 We adhered to
Declaration of Helsinki ethical guidelines, although as the
data used were from de-identified patients, informed consent
and institutional review board approval were not required.
Patient selection
We identified patients with AFL using ICD-10-CM codes
(ICD-10: I48.3 [typical AFL], I48.92 [unspecified AFL]) in
the primary diagnosis field. Patients with atypical AFL
(ICD-10: I48.4) in the primary diagnosis field were not
included. Patients with comorbid HF were identified using
the following ICD-10-CM codes in the secondary diagnosis
field: I50.2, I50.4 (heart failure with reduced ejection fraction
[HFrEF]); I50.3 (heart failure with preserved ejection frac-
tion [HFpEF]). Patients who received left atrial ablation (pre-
sumed AF or atypical AFL ablation) were excluded.
Additionally, patients with missing data on age, sex, and
mortality were also excluded. The final cohort was divided
into HFrEF (n 5 9889) and HFpEF (n 5 6063) (Figure 1).
Positive predictive values of ICD codes for AF (95%),
AFL (96%), and HF (94%) are high.9
Baseline variables
We used the variables provided in the NRD by HCUP to iden-
tify baseline characteristics including age and sex. Hospital
characteristics such as bed size, teaching status, and other
patient-specific aspects such as median household income
category for patient’s zip code, primary payer, admission
type, and admission day of the week were also recorded.10 Pa-
tient comorbidities were selected based on recognized condi-
tions that are associated with the development of HF, atrial
arrhythmias, and risk of stroke.11–13 We used the ICD-10-
CM codes to identify these patient characteristics, and these
are summarized in Supplemental Table 1.14,15
Study outcomes
The primary outcome was a composite of all-cause mortality
and/or HF readmission at 1 year. Secondary outcomes were
HF readmission, all-cause mortality, AF readmission, all-
cause readmission, and AFL readmission, all at 1 year. De-
tails about outcomes are mentioned in Supplemental Table 1.
Statistical analysis
SAS 9.4 (SAS Institute Inc, Cary, NC) and SPSS 26 (IBM
Corporation, Chicago, IL) were used for statistical analysis.
Categorical variables were compared using the c2 test and
continuous variables were compared using the Student t
test (Table 1).
A propensity to undergo catheter ablationwas generated for
every patient using all the variables listed in Table 1. Patients
with similar propensity scores in 2 groups were matched using
a 1-to-2 scheme without replacement using Greedy’s method.
The maximum propensity score differences (caliper width) of
0.05 were permitted between matched pair observations. We
used C-index to assess the appropriateness of the model. Base-
line characteristics of matched cohorts are mentioned in
Supplemental Table 2. Standardized differences were used to
assess balance diagnostics of the matched cohort
(Supplemental Figures 1 and 2). Time-to-event analysis was
conducted using Kaplan-Meier curves. The log-rank test was
used to generate P values for respective Kaplan-Meier curves.
Details of time-to-event analysis are mentioned in
Supplemental Table 3. Cox proportional hazard regression
was used to generate hazard ratios (HR) (Table 2). Subgroup
analysis of the primary outcome and secondary outcomes
was performed (Table 3 and Supplemental Table 4). Post
hoc analysis was conducted in patients without AF to increase
the internal validity of the study (Table 4). Sensitivity analysis
was conducted using Cox proportional multivariate hazard
regression adjusted for all confounders mentioned in the base-
line table (Supplemental Table 5). A 2-tailed P value of .05
was designated as statistically significant. We adhered to the
methodological standard of HCUP.16
Results
Patient selection
Our study included a total of 15,952 patients from a 2-year
period (2016–2017) with AFL and comorbid HF, in which
KEY FINDINGS
- Catheter ablation of atrial flutter in patients with heart
failure with reduced ejection fraction (HFrEF) was asso-
ciated with a lower primary composite outcome of all-
cause mortality and heart failure readmission.
- Patients with atrial flutter (AFL) and heart failure with
preserved ejection fraction (HFpEF) treated with cath-
eter ablation did not demonstrate a statistical reduc-
tion in the primary composite outcome of all-cause
mortality and heart failure readmission.
- Female patients with AFL and heart failure were less
likely to receive catheter ablation compared to male pa-
tients, despite a similar benefit.
- Future study with extended endpoints may confirm the
benefits of AFL ablation in patients with HFrEF and
possibly with HFpEF.
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9889 had HFrEF and 6063 had HFpEF. Of the patients with
AFL and concomitant HFrEF or HFpEF, 1958 (19.8%) and
897 (14.8%) patients underwent AFL ablation, respectively
(Table 1). Of note, 58.8% had coexisting AF in the HFrEF
cohort while 62.3% had AF in the HFpEF group. There
was no significant difference in terms of prevalence of AF be-
tween ablation vs no ablation in both HF subtypes.
Baseline characteristics
In the HFrEF cohort, the mean age was 67 years and 25.6% of
patients were female. Common comorbidities were
hypertension (79.5%), coronary artery disease (CAD)
(53.2%), diabetes (36.9%), chronic kidney disease (CKD)
stage 3 or more (29.4%), and chronic obstructive pulmonary
disease (COPD) (25.3%). Older patients (mean: 65 years vs
67 years, P , .001) and female patients (21.1% vs 26.7%,
P , .001) were less likely to receive ablation. Patients with
obstructive sleep apnea, obesity, hypertension, CKD stage
3 or more, and diabetes were more likely to receive ablation.
Additionally, patients at large teaching hospitals were more
likely to undergo ablation (Table 1).
In the HFpEF cohort, the mean age was 72 years and
48.8% were female. Common comorbidities included hyper-
tension (85.3%), CAD (44.9%), diabetes (41.2%), COPD
(32.9%), and obesity (31.9%). Older patients (mean: 70 years
vs 72 years, P, .001) and female patients (41.5% vs 50.1%,
P , .001) were less likely to receive catheter ablation. Pa-
tients with obstructive sleep apnea, obesity, diabetes,
COPD, and prior coronary artery bypass graft were more
likely to receive catheter ablation. Similar to the HFrEF
cohort, patients at large teaching hospitals were more likely
to receive ablation (Table 1).
Outcomes
In the HFrEF propensity score–matched cohort, we identified
1807 matched pairs (5421 patients). The median follow-up
period was 184 days. The primary outcome was significantly
lower in patients undergoing ablation compared to non-
ablation (10.7% vs 14.5%; HR 0.72, 95% confidence interval
[CI] 0.61–0.85, P, .001) (Table 2, Figure 2). For secondary
outcomes, HF readmission at 1 year (8.2% vs 10.8%; HR
0.73, 95% CI 0.61–0.89, P 5 .001), all-cause mortality at 1
Figure 1 Patient selection algorithm. HFpEF 5 heart failure with preserved ejection fraction; HFrEF 5 heart failure with reduced ejection fraction.
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Table 1 Baseline characteristics
Patients (n)
HFrEF HFpEF
No ablation Ablation Overall
P value
No ablation Ablation Overall
P value7931 1958 9889 5166 897 6063
Age (years), mean 6 SE 67 6 13 65 6 12 67 6 13 ,.001 72 6 12 70 6 11 72 6 12 ,.001
Age group, %
18–49 8.5 9.0 8.6 ,.001 3.3 4.5 3.5 ,.001
50–64 34.3 36.7 34.8 23.1 24.9 23.4
65–74 27.8 31.4 28.5 27.2 33.0 28.0
75 29.4 22.9 28.1 46.3 37.7 45.1
Sex, %
Male 73.3 78.9 74.4 ,.001 49.9 58.5 51.2 ,.001
Female 26.7 21.1 25.6 50.1 41.5 48.8
Comorbidities†
AF† 58.8 59.1 58.8 .788 61.9 65.0 62.3 .074
OSA† 16.0 19.0 16.6 .002 19.7 27.8 20.9 ,.001
Obesity† 24.8 29.0 25.7 ,.001 31.1 36.5 31.9 .002
Hypertension† 79.0 81.4 79.5 .018 85.1 86.5 85.3 .263
Diabetes† 36.3 39.5 36.9 .007 40.3 46.6 41.2 ,.001
Coronary artery disease† 53.1 53.6 53.2 .696 44.6 47.0 44.9 .167
COPD† 25.0 26.5 25.3 .182 31.9 38.2 32.9 ,.001
CKD stage 3 or more† 28.8 32.0 29.4 .005 30.8 31.3 30.9 .743
Prior CABG† 16.4 16.7 16.5 .772 12.9 16.2 13.3 .007
Hyperthyroidism† 1.6 0.9 1.5 .015 1.3 1.3 1.3 .958
Alcohol disorder† 8.6 8.5 8.6 .893 4.1 3.6 4.1 .420
Mitral valve stenosis† 0.3 0.3 0.3 .867 1.1 0.6 1.0 .123
Prior stroke/TIA† 9.9 8.9 9.7 .161 11.6 11.1 11.5 .699
Peripheral vascular disease† 7.1 6.3 7.0 .183 7.9 7.2 7.8 .490
Anemia† 17.5 18.4 17.7 .324 21.7 24.6 22.2 .054
Median household income category for
patient’s zip code‡
1. 0–25th percentile 30.7 30.2 30.6 .079 25.8 30.3 26.5 .027
2. 26–50th percentile 26.1 25.2 25.9 27.2 24.9 26.9
3. 51st–-75th percentile 24.9 23.7 24.7 25.7 25.8 25.7
4. 76th–100th percentile 18.4 20.9 18.9 21.2 19.0 20.9
Primary payer
Federal insurance 73.4 71.8 73.1 .162 83.0 82.6 83.0 .753
Private insurance 26.6 28.2 26.9 17.0 17.4 17.0
Hospital characteristics
Hospital bed sizex
Small/medium 14.2 6.1 12.6 ,.001 16.0 6.4 14.6 ,.001
Large 85.8 93.9 87.4 84.0 93.6 85.4
Hospital teaching statusk
Non-teaching 31.2 15.4 28.1 ,.001 32.7 17.7 30.5 ,.001
Teaching 68.8 84.6 71.9 67.3 82.3 69.5
Admission type
Nonelective 94.5 87.7 93.2 ,.001 94.8 85.2 93.4 ,.001
Elective 5.5 12.3 6.8 5.2 14.8 6.6
Admission day
Weekday 81.6 82.6 81.8 .314 81.5 84.9 82.0 .012
Weekend 18.4 17.4 18.2 18.5 15.1 18.0
Disposition
Home 71.5 74.3 72.0 ,.001 64.1 64.2 64.1 .063
Facility/others 28.5 24.7 28.0 35.9 35.8 35.9
In-hospital mortality 1.3 1.0 1.3 .249 1.0 0.9 1.0 .710
Length of stay (mean 6 SE) 4.8 6 0.05 6.1 6 0.11 5.0 6 0.05 ,.001 4.5 6 0.06 6.3 6 0.27 4.7 6 0.06 ,.001
AF5 atrialfibrillation; CABG5 coronary arterybypassgraft; CKD5 chronic kidneydisease; COPD5 chronicobstructivepulmonarydisease;HFpEF5heart failurewith
preserved ejection fraction; HFrEF5 heart failure with reduced ejection fraction; OSA5 obstructive sleep apnea; SE5 standard error; TIA5 transient ischemic attack.
†ICD-10 codes were used to identify respective comorbidities as per Supplemental Table 1.
‡Represents a quartile classification of the estimatedmedian household income of residents within the patients’ zip code, derived from zip code demographic data
obtained from Claritas. The quartiles are identified by values of 1 to 4, indicating the poorest to wealthiest populations. Because these estimates are updated
annually, the value ranges vary by year. https://www.hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nrdnote.jsp
xThe bed size cutoff points, divided into small, medium, and large, have been done so that approximately one-third of the hospitals in a given region, location,
and teaching status combination would fall within each bed size category. https://www.hcup-us.ahrq.gov/db/vars/hosp_bedsize/nrdnote.jsp
kA hospital is considered to be a teaching hospital if it has an American Medical Association–approved residency program, is a member of the Council of Teaching
Hospitals, or has a ratio of full-time equivalent interns and residents to beds of 0.25 or higher. https://www.hcup-us.ahrq.gov/db/vars/hosp_ur_teach/nrdnote.jsp
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year (2.8% vs 4.5%; HR 0.62, 95% CI 0.46–0.85, P5 .003),
AF readmission at 1 year (4.0% vs 6.2%; HR 0.63, 95% CI
0.48–0.82, P 5 .001), AFL readmission at 1 year (1.8% vs
6.4%; HR 0.27, 95% CI 0.19–0.39, P, .001), and readmis-
sion due to any cause at 1 year (29.7% vs 37.9%; HR 0.72,
95% CI 0.65–0.80, P , .001) were significantly lower with
AFL ablation (Table 2, Figure 3).
In the HFpEF propensity score–matched cohort, we iden-
tified 813 matched pairs (2439 patients). The median follow-
up period was 184 days. There was a trend toward reduction
in the primary outcome with ablation, but this did not reach
statistical significance (12.1% vs 14.7%; HR 0.80, 95% CI
0.63–1.01, P 5 .065) (Table 2, Figure 2). AFL readmission
at 1 year (2.9% vs 6.5%; HR 0.42, 95% CI 0.22–0.83, P 5
.012) and readmission due to any cause at 1 year (37.5% vs
43.1%; HR 0.82, 95% CI 0.71–0.94, P 5 .003) were noted
to be significantly lower in the ablation group compared to
the non-ablation group. There was no significant difference
in all-cause mortality at 1 year (3.2% vs 4.5%; HR 0.70,
95% CI 0.45–1.10, P 5 .119), HF readmission at 1 year
(9.6% vs 11.2%; HR 0.84, 95% CI 0.64–1.09, P 5 .187),
and AF readmission (5.7% vs 7.3%; HR 0.76, 95% CI
0.54–1.06, P 5 .108) between the 2 groups (Table 2,
Figure 4).
Subgroup, post hoc, and sensitivity analysis
In a subgroup analysis of the HFrEF cohort, AFL ablation
showed beneficial effects in both male and female patients
in terms of primary outcome. Patients with a history of hyper-
tension, diabetes, CAD, CKD stage 3 or more, and obesity
showed beneficial effects with ablation in regard to the pri-
mary outcome (Table 3). In a subgroup analysis of the
HFpEF cohort, patients with obesity, CKD stage 3 or more,
and peripheral vascular disease showed beneficial effects
with ablation in regard to the primary outcome (Table 3). A
post hoc analysis, after excluding patients with a diagnosis
of AF as well as a sensitivity analysis done using Cox propor-
tional multivariate hazard regression, demonstrated similar
results in both HFrEF and HFpEF subsets (Table 4,
Supplemental Table 5, Supplemental Figures 3 and 4).
Discussion
In this retrospective cohort study of patients with AFL and co-
morbid HF, patients with HFrEF who underwent AFL ablation
demonstrated significant improvement in the primary outcome
of all-cause mortality and/or HF hospitalization when compared
to patients managed medically. The maintenance of sinus
rhythm in patientswithHF has been a useful strategy to improve
Table 2 Primary and secondary outcomes in propensity-matched cohort
No ablation Ablation P value
HFrEF
Patients (n) 3614 1807
Primary outcome at 1 year (%)† 14.5 10.7 ,.001
Primary outcome at 1 year (HR, 95% CI)‡ 0.72 (0.61 – 0.85) ,.001
HF readmission at 1 year (%)† 10.8 8.2 ,.001
HF readmission at 1 year (HR, 95% CI)‡ 0.73 (0.61 – 0.89) .001
Mortality at 1 year (%)† 4.5 2.8 .003
Mortality at 1 year (HR, 95% CI)‡ 0.62 (0.46 – 0.85) .003
AF readmission at 1 year (%)† 6.2 4 .001
AF readmission at 1 year (HR, 95% CI)‡ 0.63 (0.48 – 0.82) .001
Any readmission at 1 year (%)† 37.9 29.7 ,.001
Any readmission at 1 year (HR, 95% CI)‡ 0.72 (0.65 – 0.80) ,.001
AFL readmission at 1 year (%)† 6.4 1.8 ,.001
AFL readmission at 1 year (HR, 95% CI)‡ 0.27 (0.19 – 0.39) ,.001
HFpEF
Patients (n) 1626 813
Primary outcome at 1 year (%)† 14.7 12.1 .065
Primary outcome at 1 year (HR, 95% CI)‡ 0.8 (0.63 – 1.01) .065
HF readmission at 1 year (%)† 11.2 9.6 .187
HF readmission at 1 year (HR, 95% CI)‡ 0.84 (0.64 – 1.09) .187
Mortality at 1 year (%)† 4.5 3.2 .117
Mortality at 1 year (HR, 95% CI)‡ 0.7 (0.45 – 1.1) .119
AF readmission at 1 year (%)† 7.3 5.7 .107
AF readmission at 1 year (HR, 95% CI)‡ 0.76 (0.54 – 1.06) .108
Any readmission at 1 year (%)† 43.1 37.5 .003
Any readmission at 1 year (HR, 95% CI) ‡ 0.82 (0.71 – 0.94) .003
AFL readmission at 1 year (%)† 5.9 2.2 ,.001
AFL readmission at 1 year (HR, 95% CI)‡ 0.36 (0.22 – 0.60) ,.001
AF5 atrial fibrillation; AFL5 atrial flutter; CI5 confidence interval; HF5 heart failure; HFpEF5 heart failure with preserved ejection fraction; HFrEF5 heart
failure with reduced ejection fraction; HR 5 hazard ratio.
†Log-rank test.
‡Cox proportional regression models: Individual models were run for ablation as an outcome.
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HF symptoms and also, importantly, reduce mortality.17,18 Both
AF and AFL result in a loss of atrial contribution to cardiac
output as well as inappropriate heart rates (both rapid and
slow), neurohormonal changes, and the use of antiarrhythmic
medication, which are all thought to contribute to symptoms
and mortality.17–19
Based on these data from the NRD, 15%–20% of patients
admitted with AFL and HF are treated with AFL catheter
ablation. Current guidelines recommend the use of AFL abla-
tion in patients presenting with chronic recurrent episodes or
the first episode of symptomatic AFL.20,21 Much of the evi-
dence behind these guidelines is primarily driven by small
randomized prospective studies that demonstrated low recur-
rence and low procedure-associated complication rates. The
evidence supporting the use of catheter ablation in patients
with AFL is limited, as there have not been large randomized
Table 3 Subgroup analysis of primary outcome
Primary outcome at 1 year HFrEF
HR
HFpEF
P valueSubgroups HR LL UL P value LL UL
Age
18–49 0.61 0.38 0.99 .047* 0.35 0.08 1.47 .150
50–64 0.71 0.56 0.91 .006* 1.01 0.67 1.52 .958
65–74 0.68 0.52 0.89 .006* 0.89 0.63 1.26 .515
75 0.74 0.55 0.99 .042* 0.80 0.57 1.11 .189
Sex
Male 0.73 0.62 0.87 ,.001* 0.80 0.60 1.07 .134
Female 0.60 0.44 0.83 .002* 0.94 0.70 1.26 .684
Comorbidities†
AF† 0.72 0.60 0.87 .001* 0.84 0.65 1.08 .178
OSA† 0.80 0.59 1.10 .176 0.75 0.49 1.16 .194
Obesity† 0.75 0.56 0.99 .042* 0.62 0.42 0.91 .015*
Hypertension† 0.72 0.61 0.84 ,.001* 0.85 0.68 1.05 .134
Diabetes† 0.62 0.49 0.78 ,.001* 0.74 0.54 1.00 .053*
Coronary artery disease† 0.68 0.56 0.82 ,.001* 0.84 0.62 1.13 .261
COPD† 0.86 0.69 1.07 .180 0.78 0.57 1.06 .113
CKD stage 3 or more† 0.73 0.59 0.90 .003* 0.69 0.49 0.96 .029*
Prior CABG† 0.65 0.47 0.91 .012* 0.81 0.47 1.38 .435
Hyperthyroidism† 0.90 0.20 3.91 .888 0.41 0.05 3.11 .386
Alcohol disorder† 0.95 0.60 1.45 .827 0.61 0.19 1.99 .411
Mitral valve stenosis† 1.20 0.12 11.73 .873 1.81 0.34 9.61 .488
Prior stroke/TIA† 0.82 0.54 1.24 .346 0.65 0.31 1.35 .246
Peripheral vascular disease† 0.75 0.47 1.19 .216 0.32 0.12 0.87 .025
Anemia† 0.83 0.63 1.09 .181 0.72 0.49 1.06 .096
Primary payer
Federal insurance 0.66 0.56 0.78 ,.001* 0.85 0.68 1.06 .141
Private insurance 0.91 0.66 1.26 .566 0.92 0.52 1.62 .773
Hospital characteristics
Hospital bed size‡
Small/medium 0.57 0.30 1.09 .088 0.50 0.18 1.35 .170
Large 0.70 0.60 0.81 ,.001* 0.88 0.71 1.09 .246
Hospital teaching statusx
Non-teaching 0.68 0.47 0.97 .034* 0.77 0.46 1.28 .321
Teaching 0.70 0.60 0.82 ,.001* 0.87 0.69 1.10 .232
Admission type
Nonelective 0.68 0.58 0.80 ,.001* 0.87 0.69 1.08 .203
Elective 1.12 0.69 1.81 .635 0.76 0.42 1.36 .353
Admission day
Weekday 0.71 0.60 0.83 ,.001* 0.83 0.66 1.04 .102
Weekend 0.66 0.47 0.91 .013* 1.02 0.63 1.65 .931
AF5 atrial fibrillation; CABG5 coronary artery bypass graft; CKD5 chronic kidney disease; COPD5 chronic obstructive pulmonary disease; HFpEF5 heart
failure with preserved ejection fraction; HFrEF5 heart failure with reduced ejection fraction; HR5 hazard ratio; LL5 lower limit; OSA5 obstructive sleep apnea;
TIA 5 transient ischemic attack; UL 5 upper limit.
Statistically significant P values are designated by an asterisk.
†ICD-10 codes were used to identify respective comorbidities as per Supplemental Table 1.
‡The bed size cutoff points, divided into small, medium, and large, have been done so that approximately one-third of the hospitals in a given region, location,
and teaching status combination would fall within each bed size category. https://www.hcup-us.ahrq.gov/db/vars/hosp_bedsize/nrdnote.jsp
xA hospital is considered to be a teaching hospital if it has an American Medical Association–approved residency program, is a member of the Council of Teaching
Hospitals, or has a ratio of full-time equivalent interns and residents to beds of 0.25 or higher. https://www.hcupus.ahrq.gov/db/vars/hosp_ur_teach/nrdnote.
jsp
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trials or population-wide studies addressing outcomes in HF
populations.4,22,23 Motivated by this gap, this investigation
serves as the first large-scale study that quantifies the out-
comes of patients with AFL and comorbid HF treated with
AFL catheter ablation.
Our study demonstrated a significant reduction in mortal-
ity at 1 year as well as HF readmission in those patients with
HFrEF who underwent AFL ablation. Similar findings have
been found in studies of patients with HFrEF and AF, with
significant reductions in mortality and HF readmission asso-
ciated with catheter ablation (vs pharmacologic) for mainte-
nance of sinus rhythm.24,25 Although the indication for
AFL ablation is often for heart rate control, we cannot
know in our data what prompted referral for ablation. It
may be hypothesized that AFL ablation could reverse or pre-
vent tachycardia-mediated structural remodeling, which may
reduce exacerbations of HF and overall mortality without
exposing patients to the potential adverse effects of antiar-
rhythmic drugs. Notably, our study also demonstrated a sig-
nificant reduction in AF readmission rates in patients
undergoing AFL ablation in the HFrEF cohort, suggesting
that AFL ablation may reduce atrial remodeling and progres-
sion to persistent AF.4
Additionally, patients with AFL and comorbid HFpEF
who received ablation trended toward an improved compos-
ite primary outcome, but this did not reach statistical signif-
icance.
Further analysis of the HFpEF cohort did not demonstrate
a significant reduction in mortality or HF readmissions (sepa-
rately) at 1 year in patients treated with AFL ablation. The
similar rates of all-cause mortality and HF rehospitalization
suggest that other drivers (such as uncontrolled hypertension,
diabetes, and lung disease) of HF exacerbation and disease
progression may play a larger role. A subgroup analysis
was undertaken in an attempt to identify if any subgroups
benefited from AFL ablation. HFpEF patients with obesity,
CKD, and peripheral vascular disease did show a benefit
with regard to the primary endpoint. Notably our study
showed no significant difference in rate of AF readmission
following AFL ablation in the HFpEF cohort, suggesting
that AFL is less of a contributor to AF and that features of
HFpEF such as a noncompliant ventricle and underlying
Table 4 Primary and secondary outcomes in patients without atrial fibrillation
Overall
No ablation Ablation P value
HFrEF
Patients (n) 3271 801
Primary outcome at 1 year (%)† 14.7 10.0 .001
Primary outcome at 1 year (HR, 95% CI)‡ 0.66 (0.52–0.84) .001
HF readmission at 1 year (%)† 11.0 7.7 .006
HF readmission at 1 year (HR, 95% CI)‡ 0.69 (0.52–0.90) .006
Mortality at 1 year (%)† 4.9 2.4 .002
Mortality at 1 year (HR, 95% CI) (univariate)‡ 0.48 (0.30–0.77) .002
AF readmission at 1 year (%)† 3.8 2.4 .040
AF readmission at 1 year (HR, 95% CI)‡ 0.61 (0.37–0.98) .042
Any readmission at 1 year (%)† 34.8 25.8 ,.001
Any readmission at 1 year (HR, 95% CI)‡ 0.70 (0.60–0.80) ,.001
AFL readmission at 1 year (%)† 6.8 1.5 ,.001
AFL readmission at 1 year (HR, 95% CI)‡ 0.21 (0.12–0.38) ,.001
HFpEF
Patients (n) 1970 314
Primary outcome at 1 year (%)† 12.9 11.5 .488
Primary outcome at 1 year (HR, 95% CI)‡ 0.88 (0.62–1.25) .489
HF readmission at 1 year (%)† 9.5 10.2 .713
HF readmission at 1 year (HR, 95% CI)‡ 1.07 (0.74–1.56) .713
Mortality at 1 year (%)† 4.2 2.2 .088
Mortality at 1 year (HR, 95% CI)‡ 0.52 (0.24–1.12) .094
AF readmission at 1 year (%)† 5.0 3.8 .334
AF readmission at 1 year (HR, 95% CI)‡ 0.75 (0.41–1.36) .336
Any readmission at 1 year (%)† 38.9 34.7 .137
Any readmission at 1 year (HR, 95% CI)‡ 0.86 (0.70–1.05) .138
AFL readmission at 1 year (%)† 6.5 2.9 .010
AFL readmission at 1 year (HR, 95% CI)‡ 0.42 (0.22–0.83) .012
AF 5 atrial fibrillation; AFL 5 atrial flutter; HF 5 heart failure; HFpEF 5 heart failure with preserved ejection fraction; HFrEF 5 heart failure with reduced
ejection fraction.
†Log-rank test.
‡Cox proportional regression models: Individual models were run for respective outcome.
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atriopathy may play a larger role. The addition of AF ablation
in this cohort may have a different impact on outcomes.
Further studies are required to better delineate the relation-
ship between the maintenance of sinus rhythm in patients
with HFpEF as well as the quantitative effect on morbidity
and mortality.
A recent study assessing clinical outcomes of AF abla-
tion in patients with AF and concurrent HF using the
NRD database demonstrated that in patients with HFrEF,
the composite primary outcome of mortality and HF read-
mission was not significantly different with ablation.
Conversely, in our current study, we saw significant
improvement in the composite primary outcome of mor-
tality and HF readmission in the HFrEF cohort. Although
this difference could be explained by the higher success
rate of AFL ablation compared to AF ablation, it is also
possible that adequate rate control in AFL is not achieved
and therefore nonablated patients are prone to HF decom-
pensation and are intolerant to the higher medication
doses needed for rate control, and persistent AFL may
contribute to atrial remodeling. Atrial remodeling is asso-
ciated not only with electrophysiologic changes but also
Figure 2 Kaplan-Meier curves of primary outcome in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction
(HFpEF) propensity-matched cohorts (central illustration).
60 Heart Rhythm O2, Vol 2, No 1, February 2021
with structural changes that promote both AF and atrial
dilation, worsening both mitral and tricuspid regurgita-
tion. We speculate that receiving AFL ablation and thus
controlling heart rate and perhaps preventing progression
to AF may account for this different outcome. AF ablation
at an earlier stage of atriopathy could have influenced
these findings.26
In our study, we note that female patients were less likely
to undergo ablation compared to male patients, despite
demonstrating similar benefits in outcomes in both sexes.
Previous studies have shown sex disparities in regard to fe-
male patients receiving cardiovascular treatment.27,28 The
VIRGO study,27 a prospective observational study, illus-
trated that women (,55 years) were less likely to undergo re-
perfusion therapies and were also more likely to experience
delays in receiving reperfusion therapy compared to similarly
aged men. Bhave and colleagues28 showed that female
subjects with AF had significant disparity in terms of catheter
ablation and treatment with oral anticoagulation. Patient
preferences, treatment bias, and unmeasured clinical
characteristics such as frailty were proposed as explanations
for the treatment disparity.
Finally, our study demonstrated a significant decrease in
AFL readmission that was sustained in both cohorts treated
with AFL ablation. This study, limited to patients with typical
AFL, is consistent with the high procedural success and dura-
bility of catheter ablation. This durability may contribute to
the sustained effect at maintaining sinus rhythm. As a result,
we find that the reduction in morbidity associated with AFL
readmission may be an important role for AFL ablation in pa-
tients with both HFrEF and HFpEF.29
Limitations to our study can be attributed to those of
large administrative databases such as NRD. Risk of errors
related to coding discrepancies are possible, and fidelity of
data is dependent on the rigor of coding practices of insti-
tutions submitting to this database. Furthermore, this data
set lacks information regarding medication treatments
involved in nonablative therapy. Additionally, there is no
information regarding practitioner expertise, procedural
data, antiarrhythmic drugs, and procedural success rate
for patients undergoing ablation. Our study focuses only
on patients presenting with typical AFL (right-sided) and
does not address patients with atypical AFL (left-sided).
We used a robust propensity score match algorithm to
adjust for all measurable confounders. However, propen-
sity score match does not account for unmeasured con-
founders. Despite the above-mentioned limitations, this is
the largest and only population study comparing the impact
in outcomes of ablation therapy in patients with AFL and
comorbid HF.
Figure 3 Kaplan-Meier curves of secondary outcomes in propensity-matched heart failure with reduced ejection fraction (HFrEF) cohort.
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Conclusion
In conclusion, catheter ablation in AFL patients with HFrEF
was associated with reduced all-cause mortality and/or HF
readmission as well as AF readmission. Similar effects
were not observed in the HFpEF cohort. Additionally, we
observed that female patients received less AFL ablation
compared to male patients despite demonstrating similar
beneficial outcomes. Findings from this study support the
hypothesis that sinus rhythm can play a crucial role in
reducing morbidity and mortality for patients with concur-
rent HF. Medical management of AFL may not be optimal
or even successful, as rate control is likely overestimated
and the addition of antiarrhythmics and higher doses of
HF medication may not result in higher survival or fewer
hospitalizations. More studies are needed to support and
further examine the benefits of AFL ablation for this popu-
lation.
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